RARX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RARX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ra Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2019 ($402.74 Mil) to Sep. 2019 ($547.78 Mil) and increased from Sep. 2019 ($547.78 Mil) to Dec. 2019 ($552.91 Mil).
Ra Pharmaceuticals's annual additional paid-in capital increased from Dec. 2017 ($192.38 Mil) to Dec. 2018 ($395.23 Mil) and increased from Dec. 2018 ($395.23 Mil) to Dec. 2019 ($552.91 Mil).
The historical data trend for Ra Pharmaceuticals's Additional Paid-In Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ra Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
Additional Paid-In Capital | Get a 7-Day Free Trial | 2.70 | 185.96 | 192.38 | 395.23 | 552.91 |
Ra Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec14 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | |
Additional Paid-In Capital | Get a 7-Day Free Trial | 395.23 | 398.41 | 402.74 | 547.78 | 552.91 |
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
Additional Paid-In Capital | = | (Issue Price | - | Par Value) | * | Shares Outstanding (Diluted Average) |
Thank you for viewing the detailed overview of Ra Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Kolchinsky | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Edward T Mathers | director | C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Timothy R Pearson | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Aoife Brennan | director | 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
Douglas A Treco | director, officer: President and CEO | 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
Nea Partners 13, Limited Partnership | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Nea 13 Gp, Ltd | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
New Enterprise Associates 13 Lp | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Rajeev M. Shah | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Alexander Cumbo | director | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
Robert Heft | director | 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
Patrick J Kerins | 10 percent owner | |
Ra Capital Management, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
David Charles Lubner | officer: Executive VP and CFO | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
From GuruFocus
By PRNewswire PRNewswire • 10-10-2019
By Marketwired Marketwired • 10-10-2019
By Marketwired Marketwired • 11-26-2019
By Marketwired Marketwired • 10-10-2019
By Marketwired Marketwired • 10-17-2019
By Marketwired Marketwired • 10-16-2019
By [email protected] insider • 09-20-2019
By Marketwired Marketwired • 08-15-2018
By Marketwired Marketwired • 11-01-2019
By Marketwired Marketwired • 10-15-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.